Suppr超能文献

炎症介质与代谢重编程在胰腺癌中的交互作用。

The interactive role of inflammatory mediators and metabolic reprogramming in pancreatic cancer.

机构信息

Pancreatic Cancer Section, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Pancreatic Cancer Section, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

出版信息

Trends Cancer. 2022 Jul;8(7):556-569. doi: 10.1016/j.trecan.2022.03.004. Epub 2022 May 5.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is characterized by its highly reactive inflammatory desmoplastic stroma with evidence of an extensive tumor stromal interaction largely mediated by inflammatory factors. KRAS mutation and inflammatory signaling promote protumorigenic events, including metabolic reprogramming with several inter-regulatory crosstalks to fulfill the high demand of energy and regulate oxidative stress for tumor growth and progression. Notably, the more aggressive molecular subtype of PDAC enhances influx of glycolytic intermediates. This review focuses on the interactive role of inflammatory signaling and metabolic reprogramming with emerging evidence of crosstalk, which supports the development, progression, and therapeutic resistance of PDAC. Understanding the emerging crosstalk between inflammation and metabolic adaptations may identify potential targets and develop novel therapeutic approaches for PDAC.

摘要

胰腺导管腺癌 (PDAC) 的特征是其高度活跃的炎症性纤维母细胞性基质,有大量证据表明广泛的肿瘤基质相互作用主要由炎症因子介导。KRAS 突变和炎症信号促进促肿瘤发生事件,包括代谢重编程,以及几个相互调节的交叉对话,以满足能量的高需求,并调节氧化应激以促进肿瘤生长和进展。值得注意的是,PDAC 侵袭性更强的分子亚型增强了糖酵解中间产物的流入。本综述重点关注炎症信号和代谢重编程的相互作用作用以及新兴的串扰证据,这支持了 PDAC 的发展、进展和治疗耐药性。了解炎症和代谢适应之间新兴的串扰可能为 PDAC 确定潜在的靶点并开发新的治疗方法。

相似文献

1
The interactive role of inflammatory mediators and metabolic reprogramming in pancreatic cancer.
Trends Cancer. 2022 Jul;8(7):556-569. doi: 10.1016/j.trecan.2022.03.004. Epub 2022 May 5.
3
Targets (Metabolic Mediators) of Therapeutic Importance in Pancreatic Ductal Adenocarcinoma.
Int J Mol Sci. 2020 Nov 12;21(22):8502. doi: 10.3390/ijms21228502.
4
Targeting cancer cell metabolism in pancreatic adenocarcinoma.
Oncotarget. 2015 Jul 10;6(19):16832-47. doi: 10.18632/oncotarget.4160.
5
Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies.
Cancer Lett. 2023 Apr 28;560:216138. doi: 10.1016/j.canlet.2023.216138. Epub 2023 Mar 18.
6
Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma.
Cell Death Dis. 2022 Sep 24;13(9):817. doi: 10.1038/s41419-022-05259-w.
7
A bioprinted sea-and-island multicellular model for dissecting human pancreatic tumor-stroma reciprocity and adaptive metabolism.
Biomaterials. 2024 Oct;310:122631. doi: 10.1016/j.biomaterials.2024.122631. Epub 2024 May 24.
8
PYK2 Is Involved in Premalignant Acinar Cell Reprogramming and Pancreatic Ductal Adenocarcinoma Maintenance by Phosphorylating β-Catenin.
Cell Mol Gastroenterol Hepatol. 2019;8(4):561-578. doi: 10.1016/j.jcmgh.2019.07.004. Epub 2019 Jul 19.

引用本文的文献

1
Targeting spermine metabolism to overcome immunotherapy resistance in pancreatic cancer.
Nat Commun. 2025 Aug 22;16(1):7827. doi: 10.1038/s41467-025-63146-2.
2
Understanding the heterogeneity of pancreatic ductal adenocarcinoma.
Transl Oncol. 2025 Jul 21;60:102479. doi: 10.1016/j.tranon.2025.102479.
4
Emerging therapeutics targeting tumor-associated macrophages for the treatment of solid organ cancers.
Expert Opin Emerg Drugs. 2025 Jun;30(2):109-147. doi: 10.1080/14728214.2025.2504376. Epub 2025 May 25.
5
ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer.
Carcinogenesis. 2024 Nov 22;45(11):845-856. doi: 10.1093/carcin/bgae056.
6
Hypermetabolic state is associated with circadian rhythm disruption in mouse and human cancer cells.
Proc Natl Acad Sci U S A. 2024 Jul 23;121(30):e2319782121. doi: 10.1073/pnas.2319782121. Epub 2024 Jul 15.
8
ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer.
bioRxiv. 2024 Mar 13:2024.03.12.584316. doi: 10.1101/2024.03.12.584316.

本文引用的文献

1
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.
Cancer Cell. 2022 Feb 14;40(2):201-218.e9. doi: 10.1016/j.ccell.2022.01.001. Epub 2022 Jan 28.
2
Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK Blockade, and CD40 Agonism.
Gastroenterology. 2022 Feb;162(2):590-603.e14. doi: 10.1053/j.gastro.2021.09.066. Epub 2021 Oct 8.
3
Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis.
Science. 2021 Sep 17;373(6561):eabj0486. doi: 10.1126/science.abj0486.
4
GOT1 inhibition promotes pancreatic cancer cell death by ferroptosis.
Nat Commun. 2021 Aug 11;12(1):4860. doi: 10.1038/s41467-021-24859-2.
5
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment.
Nat Rev Cancer. 2021 Aug;21(8):510-525. doi: 10.1038/s41568-021-00375-9. Epub 2021 Jul 9.
6
Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition.
Cancer Res. 2021 Jul 1;81(13):3461-3479. doi: 10.1158/0008-5472.CAN-20-2496. Epub 2021 May 12.
9
Harnessing metabolic dependencies in pancreatic cancers.
Nat Rev Gastroenterol Hepatol. 2021 Jul;18(7):482-492. doi: 10.1038/s41575-021-00431-7. Epub 2021 Mar 19.
10
Metabolic Reprogramming in Anticancer Drug Resistance: A Focus on Amino Acids.
Trends Cancer. 2021 Aug;7(8):682-699. doi: 10.1016/j.trecan.2021.02.004. Epub 2021 Mar 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验